BioWorld

Jan. 14, 2003

FDA Panel Appears To Support Genzyme's BLA For Fabry Drug

BETHESDA, Md. - An FDA panel on Monday said Genzyme General's surrogate endpoint from its Phase III trial of Fabrazyme in Fabry disease patients is likely to predict a clinically meaningful effect. (BioWorld Today) Read More

Elixir, Centagenetix Plan To Merge Complementary Aging Programs

Identifying, Isolating Adult Stem Cells Widens Path To Variety Of Futuristic Anticancer Treatments

Aventis Picks Five Eos Targets; Vaccine Deal Ends With 'Bang'

Amylin Files For $141.7M Public Offering From Shelf

BioFocus Enters Amgen Deal, Offers Warning On Financials

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

In the clinic for April 21, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...